Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Found 30047 matches for

Recognised for the part he played in the discovery of anti-TNF therapy, Dr Feldmann is now exploring whether the antibody can be effective for COVID-19.

Sir Marc Feldmann

Trials

Research groups

Oxford Trauma

Norman Collisson Foundation Scholarship

Applications for this project are now closed.

OPEN ARMS

Study with us

Events

About us

SITU

Jobs

Trials in closure

Trials in follow up

Trials under analysis

Trials open to recruitment

Trials in set-up

Themes

OCTRU runs trials across multiple areas of medicine. Within OCTRU there are five core therapeutic areas of expertise, although trials are also undertaken outside of these areas and groups.

Our studies

Lymphocyte Antigen Receptor Signaling Workshop

Information Security Policy

OTMC

Load More

Find out more about

Our Groups, Centres and Units

Our Research Themes

Our Clinical Trials

Our Programme Grants

Similar stories

TCRs drive CARs

Researchers have developed an innovative dual-receptor T-cell therapy that promises safer and more effective cancer treatments. This study, published in Cell, demonstrates that engineering T-cells to express both a Chimeric Antigen Receptor (CAR) and a T-cell Receptor (TCR) can improve their ability to distinguish between cancerous and healthy tissues—addressing a major challenge in current immunotherapy.

Common virus may improve skin cancer treatment outcomes, study finds

CRUK funding for research into earlier detection of relapse in people with multiple myeloma

New ultrasound drug delivery system found to be highly effective against bacterial biofilms

New research highlights colorectal cancer trends and survival rates

New CONSORT reporting guidelines published today in five medical journals